{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:57:49Z","timestamp":1790495869562,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.autrev.2026.104096","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T23:48:12Z","timestamp":1779752892000},"page":"104096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Racial minorities are under-represented in SLE clinical trials: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"25","author":[{"given":"Matthew A.","family":"Turk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Hausman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2026.104096_bb0005","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104096_bb0010","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/art.38238","article-title":"Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program","volume":"66","author":"Somers","year":"2014","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2026.104096_bb0020","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/art.38239","article-title":"The incidence and prevalence of systemic lupus erythematosus, 2002-2004: the Georgia Lupus Registry","volume":"66","author":"Lim","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0025","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/art.37795","article-title":"Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000\u20132004","volume":"65","author":"Feldman","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104096_bb0030","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/annrheumdis-2014-206334","article-title":"The incidence and prevalence of systemic lupus erythematosus in the UK, 1999\u20132012","volume":"75","author":"Rees","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104096_bb0035","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1002\/art.38720","article-title":"Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people, 2007-2009","volume":"66","author":"Ferucci","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105523","article-title":"New biologics and targeted therapies in systemic lupus: from new molecular targets to new indications. A systematic review","volume":"90","author":"Felten","year":"2023","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.autrev.2026.104096_bb0045","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-018-0728-2","article-title":"The representation of gender and race\/ethnic groups in randomized clinical trials of individuals with systemic lupus erythematosus","volume":"20","author":"Falasinnu","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2026.104096_bb0050","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2026.104096_bb0055","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.autrev.2026.104096_bb0060","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis Rheumatol (Hoboken)"},{"key":"10.1016\/j.autrev.2026.104096_bb0065","series-title":"Ann Rheum Dis","first-page":"183","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: Results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study","volume":"73","author":"Wallace","year":"2014"},{"key":"10.1016\/j.autrev.2026.104096_bb0070","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/rheumatology\/ket378","article-title":"Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006","volume":"53","author":"Strand","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104096_bb0075","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3899\/jrheum.121368","article-title":"Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus","volume":"41","author":"Ginzler","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0080","series-title":"Ann Rheum Dis","first-page":"1667","article-title":"A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of b cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study","volume":"74","author":"Furie","year":"2015"},{"key":"10.1016\/j.autrev.2026.104096_bb0085","series-title":"Ann Rheum Dis","first-page":"2006","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE):52-week data (April-SLE randomised trial)","volume":"74","author":"I","year":"2015"},{"key":"10.1016\/j.autrev.2026.104096_bb0090","series-title":"Arthritis Res Ther","first-page":"215","article-title":"Treatment of systemic lupus erythematosus patients with the BAFF antagonist \u201cpeptibody\u201d blisibimod (AMG 623\/A-623): Results from randomized, double-blind phase 1a and phase 1b trials","volume":"17","author":"Stohl","year":"2015"},{"key":"10.1016\/j.autrev.2026.104096_bb0095","series-title":"Ann Rheum Dis","first-page":"196","article-title":"A phase II study of the efficacy and safety of Rontalizumab (rhuMAb Interferon-alpha) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016"},{"key":"10.1016\/j.autrev.2026.104096_bb0100","series-title":"Ann Rheum Dis","first-page":"323","article-title":"Efficacy and safety of subcutaneous Tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Isenberg","year":"2016"},{"key":"10.1016\/j.autrev.2026.104096_bb0105","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","article-title":"Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled st","volume":"75","author":"Merrill","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104096_bb0110","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1177\/0961203316640910","article-title":"Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus","volume":"25","author":"Kahl","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2026.104096_bb0115","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: A randomised, double-blind, placebo-controlled study","volume":"75","author":"K","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104096_bb0120","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1177\/0961203317703495","article-title":"A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus","volume":"26","author":"Chatham","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2026.104096_bb0125","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/annrheumdis-2016-209668","article-title":"Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial","volume":"76","author":"Wallace","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104096_bb0130","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/art.39856","article-title":"Efficacy and safety of epratuzumab in moderately to severely active Systemic Lupus Erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2026.104096_bb0135","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthrit Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2026.104096_bb0140","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","article-title":"Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial","volume":"76","author":"Ordi-Ros","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104096_bb0145","series-title":"106 effects of belimumab on corticosteroid use in a pivotal phase iii, randomised, placebo controlled study in subjects with systemic lupus erythematosus in North East Asia","first-page":"A45.2","author":"Tanaka","year":"2017"},{"key":"10.1016\/j.autrev.2026.104096_bb0150","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104096_bb0155","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with Systemic Lupus Erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0160","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/art.40511","article-title":"Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive, hypocomplementemic patients with Systemic Lupus Erythematosus","volume":"70","author":"Doria","year":"2018","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2026.104096_bb0165","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active Systemic Lupus Erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104096_bb0170","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1177\/0961203318777634","article-title":"A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus","volume":"27","author":"Doria","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2026.104096_bb0175","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/art.40439","article-title":"Long-term safety and efficacy of Belimumab in patients with systemic lupus erythematosus: a continuation of a seventy-six-week phase III parent study in the United States","volume":"70","author":"Furie","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0180","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","article-title":"Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial","volume":"77","author":"Merrill","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104096_bb0185","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/annrheumdis-2018-214833","article-title":"Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER study","volume":"78","author":"Scherlinger","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"MA-L","key":"10.1016\/j.autrev.2026.104096_bb0190","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/annrheumdis-2019-eular.8720","article-title":"Headline results for a phase 4, 52-week, randomised, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive Systemic Lupus Erythematosus (SLE) receiving belimumab","volume":"78","author":"Sheikh","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104096_bb0195","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000354","article-title":"First use of cenerimod, a selective S1P 1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study","volume":"6","author":"Hermann","year":"2019","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2026.104096_bb0200","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0205","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/rheumatology\/keaa029","article-title":"Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study","volume":"59","author":"Morand","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2026.104096_bb0210","doi-asserted-by":"crossref","first-page":"E613","DOI":"10.1016\/S2665-9913(20)30223-X","article-title":"First-in-human study of JNJ-55920839 in healthy volunteers and patients with systemic lupus erythematosus: a randomised placebo-controlled phase 1 trial","volume":"2","author":"Jordan","year":"2020","journal-title":"LANCET Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0215","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/annrheumdis-2019-216379","article-title":"IFN-\u03b1 kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study","volume":"79","author":"Houssiau","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104096_bb0220","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104096_bb0225","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104096_bb0230","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cpdd.887","article-title":"Safety, tolerability, and pharmacokinetics of PF-06823859, an anti-interferon \u03b2 monoclonal antibody: a randomized, phase I, single- and multiple-ascending-dose study","volume":"10","author":"Neelakantan","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.autrev.2026.104096_bb0235","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.7326\/M21-2078","article-title":"Effectiveness of belimumab after rituximab in systemic lupus erythematosus\u00a0: a randomized controlled trial","volume":"174","author":"Shipa","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2026.104096_bb0240","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104096_bb0245","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/art.41811","article-title":"Efficacy, safety, and pharmacodynamic effects of the Bruton\u2019s Tyrosine Kinase inhibitor Fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial","volume":"73","author":"Isenberg","year":"2021","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2026.104096_bb0250","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/art.41598","article-title":"Long-term safety and efficacy of Anifrolumab in adults with Systemic Lupus Erythematosus: results of a phase II open-label extension study","volume":"73","author":"Chatham","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0255","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.autrev.2026.104096_bb0260","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1093\/rheumatology\/keab115","article-title":"Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus","volume":"60","author":"Wallace","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2026.104096_bb0265","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104096_bb0270","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000459","article-title":"Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme","volume":"8","author":"Maslen","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2026.104096_bb0275","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/S2665-9913(21)00317-9","article-title":"Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials","volume":"4","author":"Morand","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"MA-1","key":"10.1016\/j.autrev.2026.104096_bb0280","first-page":"3293","article-title":"Efficacy and safety of Cenerimod in patients with moderate to severe Systemic Lupus Erythematosus (SLE): a multicenter, randomized, parallel-group, double-blind, placebo-controlled, dose-finding phase 2b trial","volume":"74","author":"Askanase","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0285","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1136\/ard-2022-222501","article-title":"Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial","volume":"81","author":"Humrich","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104096_bb0290","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","article-title":"Phase 2 trial of Iberdomide in Systemic Lupus Erythematosus","volume":"386","author":"Merrill","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104096_bb0295","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1136\/ard-2022-222858","article-title":"Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus","volume":"81","author":"van Vollenhoven","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104096_bb0300","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104096_bb0305","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N Engl J Med"},{"issue":"Suppl. 9","key":"10.1016\/j.autrev.2026.104096_bb0310","article-title":"A phase 2, double-blind, randomized, placebo-controlled multicenter study to evaluate efficacy, safety, and tolerability of JBT-101\/Lenabasum in systemic lupus erythematosus, an autoimmunity centers of excellence study","volume":"74","author":"Mackay","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jnnp-2022-328799","article-title":"Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis","volume":"94","author":"Montalban","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2026.104096_bb0320","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/annrheumdis-2021-221847","article-title":"Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2\/3 trials","volume":"81","author":"Bruce","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104096_bb0325","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.41900","article-title":"Phase III\/IV, randomized, fifty-two-week study of the efficacy and safety of belimumab in patients of Black African ancestry with systemic lupus erythematosus","volume":"74","author":"Ginzler","year":"2022","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2026.104096_bb0330","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003302","article-title":"Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis","volume":"9","author":"Morand","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2026.104096_bb0335","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0340","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"Morand","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104096_bb0345","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1002\/art.42557","article-title":"Clinical and biomarker responses to BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: a randomized, double-blind, placebo-controlled, phase II trial","volume":"75","author":"Jayne","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0350","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2026.104096_bb0355","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/acr2.11511","article-title":"Efficacy and safety of the Bruton\u2019s tyrosine kinase inhibitor evobrutinib in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled dose-ranging trial","volume":"5","author":"Wallace","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0360","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000875","article-title":"Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE","volume":"10","author":"Askanase","year":"2023","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2026.104096_bb0365","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/art.42652","article-title":"Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: a double-blind, randomized, placebo-controlled, phase 2 trial","volume":"75","author":"Merrill","year":"2023","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2026.104096_bb0370","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2665-9913(23)00320-X","article-title":"Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial","volume":"6","author":"Chakravarty","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0375","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/art.1780380415","article-title":"The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth","volume":"38","author":"Johnson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104096_bb0380","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.41632","article-title":"Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries","volume":"73","author":"Izmirly","year":"2021","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2026.104096_bb0385","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40985-016-0025-4","article-title":"Improving the health of African Americans in the USA: an overdue opportunity for social justice","volume":"37","author":"Noonan","year":"2016","journal-title":"Public Health Rev"},{"key":"10.1016\/j.autrev.2026.104096_bb0390","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/acr.24635","article-title":"Using critical race theory to understand trial participation among black individuals with systemic lupus erythematosus: a qualitative study of patients and caregivers","volume":"73","author":"Sneed","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2026.104096_bb0395","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1200\/JCO.2017.73.6546","article-title":"Charting the future of cancer health disparities research: a position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute","volume":"35","author":"Polite","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.autrev.2026.104096_bb0400","unstructured":"Shi-kai Geng, Hui-jing Wang, Liang-jing L\u00fc, Wei-guo Wan, Fang-fang Sun, Shuang YE. Effect of metformin on infection event reduction in patients with systemic lupus erythematosus: a post-hoc analysis of a Met-Lupus Trial. J Shanghai Jiao Tong Univ Med Sci 00:00:00.0;41:473\u20138."},{"key":"10.1016\/j.autrev.2026.104096_bb0405","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104096_bb0410","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/annrheumdis-2022-eular.5086a","article-title":"Orelabrutinib, an irreversible inhibitor of Bruton\u2019s tyrosine kinase (BTK), for the treatment of systemic lupus erythematosus (SLE): results of a randomized, double-blind, placebo-controlled, phase IB\/IIA dose-finding study","volume":"81","author":"Li","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104096_bb0415","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2026.104096_bb0420","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2020-217178","article-title":"Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis","volume":"79","author":"Mok","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104096_bb0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/316965","article-title":"The effects of bromocriptine on preventing postpartum flare in systemic lupus erythematosus patients from South China","volume":"2015","author":"Qian","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.autrev.2026.104096_bb0430","doi-asserted-by":"crossref","first-page":"E210","DOI":"10.1016\/S2665-9913(20)30004-7","article-title":"Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"2","author":"Sun","year":"2020","journal-title":"LANCET Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0435","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/14397595.2019.1583832","article-title":"Safety and tolerability of sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in Japanese patients with systemic lupus erythematosus: a multicenter, phase 2, open-label study","volume":"30","author":"Takeuchi","year":"2020","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0440","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/14397595.2018.1480915","article-title":"Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: a subgroup analysis of a phase 3 randomized placebo-controlled trial","volume":"29","author":"Tanaka","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0445","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104096_bb0450","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104096_bb0455","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.4492","article-title":"Effect of tacrolimus vs intravenous cyclophosphamide on complete or partial response in patients with Lupus nephritis: a randomized clinical trial","volume":"5","author":"Zheng","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.autrev.2026.104096_bb0460","article-title":"Bias caused by sampling error in meta-analysis with small sample sizes","volume":"13","author":"Lin","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2026.104096_bb0465","doi-asserted-by":"crossref","first-page":"1286121","DOI":"10.3389\/fpubh.2024.1286121","article-title":"An intersectionality framework for identifying relevant covariates in health equity research","volume":"12","author":"Simkus","year":"2024","journal-title":"Front Public Health"},{"key":"10.1016\/j.autrev.2026.104096_bb0470","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0961203318816820","article-title":"Is systemic lupus erythematosus different in urban versus rural living environment? Data from the Cretan Lupus Epidemiology and Surveillance Registry","volume":"28","author":"Gergianaki","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2026.104096_bb0475","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/rheumatology\/keac613","article-title":"The impact of social determinants of health on the presentation, management and outcomes of systemic lupus erythematosus","volume":"62","author":"Williams","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2026.104096_bb0480","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/acr2.11590","article-title":"Disparities in lupus and the role of social determinants of health: current state of knowledge and directions for future research","volume":"5","author":"Buie","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0485","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1053\/j.ackd.2014.06.005","article-title":"APOL1 kidney risk alleles: population genetics and disease associations","volume":"21","author":"Limou","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.autrev.2026.104096_bb0490","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1007\/s10067-022-06268-y","article-title":"Health disparities in systemic lupus erythematosus-a narrative review","volume":"41","author":"Hasan","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0495","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/acr2.1024","article-title":"Unraveling race, socioeconomic factors, and geographical context in the heterogeneity of lupus mortality in the United States","volume":"1","author":"Falasinnu","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.autrev.2026.104096_bb0500","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cct.2014.08.004","article-title":"Strategies addressing barriers to clinical trial enrollment of underrepresented populations: a systematic review","volume":"39","author":"Heller","year":"2014","journal-title":"Contemp Clin Trials"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:29:22Z","timestamp":1790494162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":100,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1568997226001102"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104096","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Racial minorities are under-represented in SLE clinical trials: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104096"}}